The outlook of companies tied to Sildenafil's history presents a challenging investment picture . While the initial boom generated substantial returns , generic copies have significantly impacted revenue. Investing in related pharmaceutical companies now requires a thorough assessment of intellectual property protection , evolving healthcare shifts